MediciNova, Inc. MNOV NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

40/100

2/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

MediciNova, Inc. (MNOV) has a negative trailing P/E of -5.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -16.98%, forward earnings yield 46.95%. PEG 0.02 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

VALUE (0/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -5.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -16.98%).
Forward P/E 2.1 — analysts expect a return to profitability with estimated EPS of $0.66 for FY2029.
PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Trailing Earnings Yield -16.98% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 46.95% as earnings recover.

Overall SharesGrow Score: 39/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

40/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

✗

GROWTH

30/100

→ Income

✗

INCOME

10/100

→ Income

Valuation Snapshot — MNOV

Valuation Multiples

P/E (TTM)-5.9

Forward P/E2.1

PEG Ratio0.02

Forward PEG0.02

P/B Ratio1.70

P/S Ratio173.02

EV/EBITDA-3.2

Per Share Data

EPS (TTM)$-0.24

Forward EPS (Est.)$0.66

Book Value / Share$0.85

Revenue / Share$0.01

FCF / Share$-0.20

Yields & Fair Value

Earnings Yield-16.98%

Forward Earnings Yield46.95%

Dividend Yield0.00%

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2016	-18.3	0.00	5.76	0.00	-
2017	-20.4	6.72	5.88	0.00	-
2018	-22.9	-1.83	4.60	0.00	-
2019	-22.5	1.35	3.88	0.00	-
2020	-16.9	-5.06	3.28	0.00	-
2021	-12.9	0.40	1.56	32.26	-
2022	-7.1	-0.19	1.43	0.00	-
2023	-8.6	0.21	1.18	73.57	-
2024	-9.3	-0.26	1.96	0.00	-
2025	-5.4	-1.23	1.55	156.89	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2016	$-0.33	$0.00	$-10.87M	-
2017	$-0.32	$0.00	$-11.16M	-
2018	$-0.36	$0.00	$-14.68M	-
2019	$-0.30	$0.00	$-12.94M	-
2020	$-0.31	$0.00	$-13.85M	-
2021	$-0.21	$4.04M	$-10.13M	-251%
2022	$-0.29	$0.00	$-14.07M	-
2023	$-0.17	$1M	$-8.57M	-857.2%
2024	$-0.23	$0.00	$-11.05M	-
2025	$-0.24	$409.66K	$-12M	-2928.8%

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.31	$-0.31 – $-0.31	$166.67K	$166.67K – $166.67K	2
2027	$-0.40	$-0.40 – $-0.40	$700K	$700K – $700K	2
2028	$-0.11	$-0.44 – $0.29	$42.69M	$42.69M – $42.69M	3
2029	$0.66	$0.66 – $0.66	$97.61M	$97.61M – $97.61M	1
2030	$1.60	$1.60 – $1.60	$202.19M	$202.19M – $202.19M	1